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The synthesis of bile acids from cholesterol is a complex
process requiring modifications of both the steroid nucleus and
the aliphatic side chain (reviewed in Refs. 1 and 2). Cholic acid
and chenodeoxycholic acid, the two primary bile acids in humans, are synthesized in the liver via the concerted action of
enzymes located in the endoplasmic reticulum, cytosol, mitochondria, and peroxisomes. The immediate precursors of the
C24 bile acids cholate and chenodeoxycholate are the C27 com-
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pounds 3␣,7␣,12␣-trihydroxy-5␤-cholestanoic acid (THCA)1
and 3␣,7␣-dihydroxy-5␤-cholestanoic acid (DHCA), respectively (1, 2). It is well established that chain shortening of the
methyl-branched side chain of THCA and DHCA by ␤-oxidation
takes place in peroxisomes (3). For ␤-oxidation to occur, THCA
and DHCA must first be activated to their CoA thioesters. The
products of chain shortening are choloyl-CoA and chenodeoxycholoyl-CoA and not the free bile acids (4).
The CoA thioesters of the primary bile acids are conjugated
to the amino acid glycine or taurine in the hepatocyte before
secretion into the bile canaliculi (1, 2). After bile secretion into
the intestine during digestion, the conjugated primary bile
acids are subject to deconjugation, 7␣-dehydroxylation, and
other modifications by the intestinal flora (1, 5). 7␣-Dehydroxylation converts conjugated or unconjugated cholate to deoxycholate, and chenodeoxycholate to lithocholate. Deoxycholate
and lithocholate are referred to as secondary bile acids. A
substantial portion of the intestinal bile acid pool is reabsorbed
by passive diffusion throughout the small bowel and by active
transport in the distal ileum; all of these compounds return to
the liver via the enterohepatic circulation for reutilization (6).
Recycled unconjugated primary and secondary bile acids must
then be re-conjugated to glycine or taurine before return to the
bile. However, re-conjugation can occur only after the free acids
are activated to their CoA derivatives.
We recently demonstrated that human very long-chain acylCoA synthetase homolog 2 (hVLCS-H2), a liver-specific member of the protein family that includes very long-chain acyl-CoA
synthetases (VLCSs) and fatty acid transport proteins, is a
choloyl-CoA synthetase (7). We hypothesized that a major function of this protein is to activate recycled bile acids prior to
their re-conjugation. In this report, we provide further evidence
for a role for hVLCS-H2 in activation of primary and secondary
bile acids. Furthermore, we demonstrate that hVLCS and
hVLCS-H2 are capable of activating the cholic acid precursor
(THCA) and speculate on the complementary role of these
proteins in bile acid synthesis. Based on the substrate specificity of hVLCS-H2, we will hereafter refer to this protein as
human bile acyl-CoA synthetase (hBACS).

1
The abbreviations used are: THCA, 3␣,7␣,12␣-trihydroxy-5␤-cholestanoic acid; DHCA, 3␣,7␣-dihydroxy-5␤-cholestanoic acid; hVLCS,
human very long-chain acyl-CoA synthetase; hVLCS-H1 and hVLCSH2, hVLCS homologs 1 and 2, respectively; hBACS, human bile acylCoA synthetase; EST, expressed sequence tag; HPLC, high-performance liquid chromatography; rACS1, rat liver long-chain acyl-CoA
synthetase-1.
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Bile acids are synthesized de novo in the liver from
cholesterol and conjugated to glycine or taurine via a
complex series of reactions involving multiple organelles. Bile acids secreted into the small intestine are
efficiently reabsorbed and reutilized. Activation by thioesterification to CoA is required at two points in bile
acid metabolism. First, 3␣,7␣,12␣-trihydroxy-5␤-cholestanoic acid, the 27-carbon precursor of cholic acid, must
be activated to its CoA derivative before side chain
cleavage via peroxisomal ␤-oxidation. Second, reutilization of cholate and other C24 bile acids requires reactivation prior to re-conjugation. We reported previously
that homolog 2 of very long-chain acyl-CoA synthetase
(VLCS) can activate cholate (Steinberg, S. J., Mihalik,
S. J., Kim, D. G., Cuebas, D. A., and Watkins, P. A. (2000)
J. Biol. Chem. 275, 15605–15608). We now show that this
enzyme also activates chenodeoxycholate, the secondary bile acids deoxycholate and lithocholate, and
3␣,7␣,12␣-trihydroxy-5␤-cholestanoic acid. In contrast,
VLCS activated 3␣,7␣,12␣-trihydroxy-5␤-cholestanoate,
but did not utilize any of the C24 bile acids as substrates.
We hypothesize that the primary function of homolog 2
is in the reactivation and recycling of C24 bile acids,
whereas VLCS participates in the de novo synthesis
pathway. Results of in situ hybridization, topographic
orientation, and inhibition studies are consistent with
the proposed roles of these enzymes in bile acid
metabolism.
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EXPERIMENTAL PROCEDURES

Expressed sequence tag (EST) clones representing the murine homolog of hVLCS were identified by homology probing of the EST data
base using rat VLCS cDNA sequence (13) as the query. An EST clone
(GenBankTM accession number AA038113) containing the C-terminal
921 base pairs of the open reading frame plus 8 bp of the 3⬘-untranslated region was obtained from Genome Systems, Inc. The EST clone
insert was moved to the mammalian cloning vector pcDNA3 using
EcoRI and NotI. The 5⬘-untranslated region of rat VLCS (13) was used
to design a forward PCR primer (5⬘-CGCGGGTACCGATCTCACCTGACCCCAGACG-3⬘) with an engineered KpnI site and to amplify the
5⬘-end of mouse VLCS from liver total cDNA with a reverse primer
(5⬘-tgccttcagtggatgcgtagaac-3⬘). The ⬃1100-bp PCR product encompassed a second KpnI site near the 3⬘-end. Both KpnI sites in the PCR
fragment were used to clone the PCR fragment into a KpnI site near the
5⬘-end of EST AA038113 in pcDNA3, and the clone was re-sequenced.
The full-length open reading frame of mouse VLCS was deposited in the
GenBankTM/EBI Data Bank (accession number AF033031).
The completed mouse VLCS cDNA sequence was used to search the
EST data base for related mouse ESTs. ESTs AA106121 and AA538033
both contained full-length cDNA encoding the murine homolog of
hBACS. The insert of EST AA106129 was released by digestion with
AccI and SpeI and was blunt-ended with Klenow enzyme. The fragment
was then cloned into the EcoRV site of pcDNA3, and the clone was
sequenced.
In most expression experiments, COS-1 cells (a gift of Dr. C. Thompson) were transfected with 10 g of plasmid DNA by electroporation as
described previously (8). In some experiments, cells were transfected
using GeneSHUTTLE-40 (Qbiogene, Inc.). 10 g of plasmid DNA was
mixed with 30 l of GeneSHUTTLE-40 and incubated with COS-1 cells
in serum-free medium for 8 h. Following addition of an equal volume of
culture medium containing 20% fetal bovine serum, cell incubation was
continued for 16 h. At this time, the culture medium was replaced with
culture medium containing 10% fetal bovine serum, and the cells were
harvested 72 h post-transfection. Washed cell pellets were resuspended
in 0.25 M sucrose containing 10 mM Tris (pH 8.0) and 1 mM EDTA,
frozen at ⫺80 °C for a minimum of 4 h, and thawed on ice for assay.
Indirect Immunofluorescence—COS-1 cells were transfected as described above with hVLCS or hBACS containing the c-myc epitope
in-frame at either the N or C terminus of the protein. After 3 days, cells
were fixed in 4% formaldehyde in phosphate-buffered saline and solubilized with either 1.0% Triton X-100 or 15 g/ml digitonin prior to
incubation with primary and secondary antibodies as described previously (14).
Bile Acyl-CoA Synthetase and Fatty Acyl-CoA Synthetase Assays—
Both isotopic and high-performance liquid chromatography (HPLC)based assays of bile acid activation were performed as previously described (7), with the following exceptions. The poorly soluble sodium
salt of lithocholate was dried on the bottom of reaction tubes and was
solubilized using 50 l of ␤-cyclodextrin (10 mg/ml) in 10 mM Tris (pH
8.0) by brief sonication prior to addition of other reaction components
and enzyme. In the experiments shown in Figs. 1C and 3B, the gradient
program for elution of bile acyl-CoA derivatives from the reverse-phase
HPLC column (25– 65% solvent B over 30 min), which deviated from the
previously described method (25–50% solvent B over 25 min) (7). The
unlabeled THCA used in these experiments also contained ⌬24-THCA
(8%, w/w). In the HPLC tracing shown in Fig. 1D, peak 3 was tentatively identified as the CoA derivative of ⌬24-THCA. The retention time
of this product was identical to that of ⌬24 THCA-CoA produced from
the incubation of 24-hydroxy-THCA (varanoyl-CoA) with fibroblasts
from patients with mutations in the 3-hydroxyacyl-CoA dehydrogenase
domain of peroxisomal D-bifunctional protein. Tracings from patients
with mutations in the enoyl hydratase portion of the gene had severe
reductions in this product, as described previously (15). For inhibition
experiments (see Fig. 3B), (25S)-THCA-CoA was quantitated using a
Hewlett-Packard 3392A integrator. Activation of [1-14C]palmitic acid by
transfected COS-1 cells was measured as previously described (8).
In Situ Hybridization—The method of Giger et al. (16) was used, with
modification. Plasmids containing full-length cDNA encoding the murine homologs of VLCS and BACS in pcDNA3 were linearized by cutting
at a restriction site upstream of the initiator methionine codon (for
antisense probes) or just downstream of the stop codon (for sense
probes). Antisense RNA probes for VLCS (1865 bp) and BACS (2071 bp)
were synthesized using digoxigenin-labeled UTP (Roche Molecular Biochemicals) and SP6 RNA polymerase (Ambion Inc.). The corresponding
digoxigenin-labeled sense probes were synthesized for use as controls
using T7 RNA polymerase (Ambion Inc.). Livers obtained from adult
mice were quick-frozen in liquid nitrogen. Slices (8 m) were obtained
using a Microm HM500M cryostat, collected on Superfrost Plus slides
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Materials and General Methods—Sodium salts of cholic, chenodeoxycholic, deoxycholic, and lithocholic acids were obtained from either
Steraloids, Inc. (Wilton, NH) or Sigma. [1-14C]Cholic acid (55 mCi/
mmol) and [1-14C]chenodeoxycholic acid (51.3 mCi/mmol) were obtained
from American Radiolabeled Chemicals. [1-14C]Palmitic acid (50 mCi/
mmol) was from Moravek Biochemicals, Inc. The PCR conditions were
as previously described (8). Protein was determined by the method of
Lowry et al. (9).
Synthesis of THCA and [26-14C]THCA—⌬24-THCA was synthesized
by the method of Xu and Cuebas (10). Unlabeled THCA was prepared by
the catalytic hydrogenation of ⌬24-THCA using Adams’ catalyst (Aldrich) suspended in methanol at 1-atmosphere pressure for 12 h. The
product is a racemic mixture of (25S)- and (25R)-THCA stereoisomers.
[26-14C]THCA was prepared from THCA by a modification of the
method of Tserng and Klein (11). THCA was formylated to protect the
hydroxyl groups by heating 0.24 mmol in 1 ml of 90% formic acid
containing 0.025 ml of 70% perchloric acid for 2 h at 55 °C. After cooling
to ⬃45 °C and dropwise addition of acetic anhydride until massive
bubbling occurred, the solution was further cooled to room temperature,
and the formylated THCA was extracted with diethyl ether and dried
(85% yield). The corresponding 25-chloronorcholane was then obtained
by dissolving 0.2 mmol of the formylated THCA in 2.5 ml of dry benzene
containing 0.4 mmol of lead tetraacetate and 0.4 mmol of LiCl and
heating to 85 °C for 3 h. At this time and again at 4 h, 0.2 mmol of LiCl
was added. The reaction mixture was then cooled, centrifuged to remove precipitated material, washed with ice-cold 2% NaOH and ice-cold
water, dried with MgSO4, and evaporated to dryness to afford 25-chloro3␣,7␣,12␣-triformyloxynorcholane (75% yield). 40 mol of this product
was dissolved in 1 ml of dry dimethyl sulfoxide containing 2.0 mCi of
Na14CN (36 mol, 55 mCi/mmol) and heated for 32 h at 70 °C. After
cooling, 1 ml of 2 N NaOH was added, and the solution was heated to
90 °C for 1 h to hydrolyze the formyl groups. The product (cyano3␣,7␣,12␣-trihydroxy[26-14C]norcholane) was then extracted with chloroform, dried, and purified by preparative thin-layer chromatography
in cyclohexane/ethyl acetate/acetic acid (21:69:9; 1.55 mCi; 77% yield).
Finally, the purified nitrile was dissolved in 2 ml of ethanol and 10%
aqueous NaOH (2:1) and heated to 80 °C for 40 h. After cooling, the
reaction mixture was concentrated to one-third of its original volume to
remove ethanol and restored again to its original volume by adding
water. After acidification, the reaction product was extracted with
chloroform. Analysis by thin-layer and gas-liquid chromatography
showed that the reaction product was identical to THCA (1.22 mCi; 79%
yield).
Cloning and Expression of VLCS and BACS Constructs—Full-length
cDNAs encoding hVLCS and hBACS were cloned into the expression
vector pcDNA3 (Invitrogen) as previously described (8, 12). Cloning of
N-myc-hBACS was also described previously (12).
For production of N-myc-hVLCS, the full-length open reading frame
of hVLCS was amplified by PCR using oligonucleotide primers P0-17
(5⬘-CCCGTCGACCATGCTTTCCGCCATCTACA-3⬘, which incorporates
a SalI restriction site) and P0-4 (5⬘-GTCTGCGGCCGCCCTCCAACAAGCTCAGTTTGC-3⬘, which incorporates a NotI site) with hVLCS
in pcDNA3 as template. The product was ligated into the XhoI and NotI
sites of N-myc-pcDNA3, a modified pcDNA3 vector that places the c-myc
epitope in-frame at the amino terminus (a gift of Dr. S. Gould).
To produce C-myc-hVLCS, a three-fragment ligation was performed.
A 1614-bp fragment containing the initiator methionine codon was
excised from hVLCS in pcDNA3 using BamHI and BglI. A 550-bp
fragment of hVLCS in which the stop codon was replaced by a HindIII
restriction site was amplified by PCR using hVLCS in pcDNA3
as template and oligonucleotide primers P0-5 (5⬘-AGCAAAGGCTCAGACAGAGA-3⬘, forward) and P0-19 (5⬘-CCGAAGCTTGAGTTTCAGGGTTTTAGC-3⬘, reverse); this fragment was cut with BglI and
HindIII, yielding a 477-bp fragment. These two pieces were ligated into
the BamHI and HindIII sites of pcDNA3.1-myc-HisA (Invitrogen), forming C-myc-hVLCS.
A similar approach was used to produce C-myc-hBACS. A 1801-bp
fragment containing the start codon was excised from hBACS in
pcDNA3 using KpnI and NheI. A 422-bp fragment of hBACS in which
the stop codon was replaced by a HindIII restriction site was amplified
by PCR using hBACS in pcDNA3 as template with oligonucleotide
primers P2-9 (5⬘-CGCCTCGGGGACACCTTC-3⬘, forward) and P2-18
(5⬘-TTTAAGCTTGAGCCTCCAGGTTCCCTC-3⬘, reverse); this fragment was cut with NheI and HindIII, yielding a 270-bp fragment. These
two pieces were ligated into the KpnI and HindIII sites of
pcDNA3.1-myc-HisA, forming C-myc-hBACS.
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(Fisher), fixed for 30 min with 4% paraformaldehyde in phosphatebuffered saline, and acetylated for 10 min in 0.25% acetic anhydride in
0.1 M triethanolamine. After 8 h of prehybridization in 50% formamide
containing 5⫻ Denhardt’s solution (Sigma), 5⫻ SSC, and 0.25 mg/ml
yeast tRNA (Invitrogen), slices were hybridized in the same buffer
containing digoxigenin-labeled probes (200 ng/ml) for 16 h at 60 °C. The
slides were washed under high-stringency conditions (5⫻ SSC in 50%
formamide for 5 min at 59 °C, 2⫻ SSC for 1 min at 59 °C, 0.2⫻ SSC for
30 min at 65 °C, and 0.2% SSC for 5 min at room temperature). After a
1-h incubation in blocking reagent (Roche Molecular Biochemicals),
slices were incubated for 1.5 h with alkaline phosphatase-conjugated
anti-digoxigenin antibody (Roche Molecular Biochemicals). Color development with nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl
phosphate was carried out for 16 h.
RESULTS

hBACS Catalyzes Activation of Primary and Secondary Bile
Acids—We previously showed that when expressed in COS-1
cells, hBACS (formerly called hVLCS-H2, a member of the
VLCS/fatty acid transport protein family of acyl-CoA synthetases) catalyzes the activation of cholic acid to its CoA derivative
(7). This observation was consistent with the tissue (liver) and
subcellular (endoplasmic reticulum) distribution of this protein
(17, 18). We also reported that hBACS weakly activates the
very long-chain fatty acid lignoceric acid (C24:0; 20 – 40% of the
activity measured with cholate) and was not able to activate
the long-chain fatty acid palmitic acid (C16:0) (7, 12). To determine whether the other human primary bile acid, chenodeoxycholic acid, and the secondary bile acids deoxycholic acid and
lithocholic acid are also substrates for hBACS, we incubated
these compounds with ATP, MgCl2, CoA and freeze/thaw-disrupted COS-1 cells expressing this or related proteins. The
products were separated by HPLC as previously described (7).
When chenodeoxycholate was the substrate, a product with a

retention time of 20.3 min was detected in cells expressing
hBACS (Fig. 1A). No product was detected in cells transfected
with hVLCS, hVLCS-H1, rat liver long-chain acyl-CoA synthetase-1 (rACS1), or the vector (pcDNA3) alone (Fig. 1A). We had
previously reported that no product is formed in the absence of
ATP, CoA, or the bile acid substrate (7) (data not shown). To
substantiate the results of the HPLC-based assay, we incubated COS-1 cells expressing hBACS and related proteins with
radiolabeled chenodeoxycholate (Fig. 2A). Again, only cells expressing hBACS were capable of catalyzing chenodeoxycholate
activation. Thus, we conclude that chenodeoxycholate is also a
substrate for hBACS.
Similar results were obtained using the HPLC-based assay
when the secondary bile acids deoxycholate (Fig. 1B) and lithocholate (Fig. 1C) were substrates for activation by hBACS. The
putative products deoxycholoyl-CoA and lithocholoyl-CoA
eluted at 21.7 and 19.7 min, respectively. No product was
detected with either substrate in cells expressing hVLCS,
hVLCS-H1, or rACS1, consistent with the hypothesis that the
liver-specific hBACS is a bile acyl-CoA synthetase capable of
activating both primary and secondary bile acids.
Both hVLCS and hBACS Activate the Bile Acid Precursor
THCA—Based on the above observations, we predicted that the
C27 precursor of cholic acid (THCA) would be activated to its
CoA derivative by hBACS, but not by the other hVLCSs or
rACS1. When THCA was incubated with ATP, MgCl2, CoA, and
COS-1 cells expressing hBACS, three product peaks were seen
on the HPLC tracing (Fig. 1D). The substrate used is a racemic
mixture of (25S)- and (25R)-THCA stereoisomers. It was previously shown that the physiologic isomer ((25S)-THCA) elutes
slightly earlier than the non-physiologic isomer ((25R)-THCA)
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FIG. 1. Activation of bile acids and
THCA by hVLCS and hBACS. COS-1
cells were transfected with full-length
cDNA encoding hVLCS, hVLCS-H1,
hBACS, or rACS1 or with the vector
(pcDNA3) alone; harvested 72 h posttransfection; disrupted by freeze/thaw;
and incubated for 20 min at 37 °C with
ATP, MgCl2, CoA, and the indicated substrate at 20 M. Products were analyzed
by reverse-phase HPLC as described under “Experimental Procedures.” Shown is
the activation of chenodeoxycholate (A),
deoxycholate (B), lithocholate (C), and
THCA (D). In D, peak 1 is (25S)-THCACoA, peak 2 is (25R)-THCA-CoA, and
peak 3 is ⌬24-THCA-CoA. Two to three
independent transfection experiments
yielded identical results.
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in a similar HPLC system (19). Thus, we have provisionally
designated peak 1 (23.4 min) as (25S)-THCA and peak 2 (23.7
min) as (25R)-THCA. Peak 3 had a retention time (22.3 min)
identical to that of 3␣,7␣,12␣-trihydroxy-5␤-cholest-24-en-26oyl-CoA (see “Experimental Procedures”) (data not shown).
This compound is the product formed by the action of peroxisomal branched-chain acyl-CoA oxidase on (25S)-THCA and
accumulates when fibroblasts from children with mutations in
the 3-hydroxyacyl-CoA dehydrogenase domain of peroxisomal
D-bifunctional protein are incubated with 24-OH-THCA (15).
Similar to the situation with primary and secondary bile
acids, no product was detected when THCA was incubated with
COS-1 cells expressing hVLCS-H1, rACS1, or the vector alone
(Fig. 1D). In contrast, cells expressing hVLCS (which were not
capable of activating the bile acids) yielded the same three
product peaks as did cells expressing hBACS (Fig. 1D). This
observation suggests that both hVLCS and hBACS are capable
of activating THCA for its subsequent conversion to cholate.
The ability of hVLCS and hBACS to activate THCA was
confirmed by radiochemical assay using [26-14C]THCA as substrate. COS-1 cells expressing either hVLCS or hBACS exhibited THCA-CoA synthetase activity (Fig. 2B). COS-1 cells
transfected with the vector (pcDNA3) alone, hVLCS-H1, or
rACS1 were unable to activate [26-14C]THCA (Fig. 2B).
THCA Inhibits hBACS-catalyzed Activation of Cholate—To
elucidate the role(s) of hVLCS and hBACS in bile acid metabolism, we first investigated the ability of the biosynthetic precursor of cholate (THCA) to inhibit cholate activation. We incubated COS-1 cells expressing hBACS with radiolabeled
cholate in the presence of increasing concentrations of THCA. A

FIG. 3. Inhibition of hVLCS and hBACS by cholate and THCA.
A, THCA inhibition of [1-14C]cholate activation by hBACS. COS-1 cells
expressing hBACS were incubated with 20 M [1-14C]cholate and the
indicated concentration of unlabeled THCA. The production of labeled
choloyl-CoA was quantitated as described under “Experimental Procedures.” The results are the means ⫾ S.E. from three separate transfection experiments. B, cholate inhibition of THCA activation by hVLCS or
hBACS. COS-1 cells expressing hVLCS (E) or hBACS (‚) were incubated with 20 M THCA and the indicated concentration of cholate.
Production of (25S)-THCA-CoA was quantitated by reverse-phase
HPLC as described under “Experimental Procedures.” The results are
expressed as percent of the control (no cholate) and are the means of two
separate transfections.

concentration of THCA (4 M) that was 20% of the cholate
concentration (20 M) reduced cholate activation by nearly half
(Fig. 3A). When THCA was present at the same (20 M) and at
double (40 M) the cholate concentration, we observed 72 and
82% inhibition, respectively (Fig. 3A).
Cholate Inhibits Activation of THCA by hBACS, but Not by
hVLCS—Because cholate is a substrate for hBACS, but not for
hVLCS, we next examined the effect of unlabeled cholate on
THCA activation by these two enzymes. When COS-1 cells
expressing hBACS were incubated with 20 M THCA, formation of (25S)-THCA-CoA was reduced by 11, 21, and 39% when
4, 20, and 40 M cholate, respectively, were present in the assay
(Fig. 3B). In contrast, with COS-1 cells expressing hVLCS, an
enzyme that does not activate cholate, there was no apparent
cholate inhibition of THCA activation (Fig. 3B).
Kinetic Studies of Cholate and Palmitate Activation—Kinetic
studies were performed to establish further that hVLCS does
not activate bile acids and that hBACS does not activate longchain fatty acids. COS-1 cells expressing hBACS exhibited
normal Michaelis-Menten kinetics when cholate was the substrate (Fig. 4A); cells transfected with the vector alone had no
activity with this substrate (data not shown). Under these
conditions, the Km of hBACS for cholate was 2.8 M, and the
Vmax was 3.8 nmol/20 min/mg of COS cell protein, as determined by nonlinear regression analysis. Similar experiments
were performed using the substrate palmitic acid (C16:0), a
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FIG. 2. Activation of radiolabeled chenodeoxycholate and
THCA by hVLCS and hBACS. COS-1 cells expressing hVLCS,
hVLCS-H1, hBACS, rACS1, or the vector alone were incubated with
ATP, MgCl2, CoA, and 20 M [1-14C]chenodeoxycholate (A) or 20 M
[26-14C]THCA (B). After 20 min, labeled CoA derivatives were extracted
from the reaction mixture, and the radioactivity was determined as
described under “Experimental Procedures.” The results in A are the
means ⫾ S.E. from three separate transfection experiments. Because of
the limited availability of [26-14C]THCA, the results in B are the mean
of two separate transfections. N.D., not determined.
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long-chain fatty acid that is the preferred substrate for hVLCS
(8). Kinetic analysis is complicated by the fact that untransfected and vector-transfected COS-1 cells contain several endogenous acyl-CoA synthetases that can activate C16:0 (see Fig.
4B); thus, endogenous activity must be subtracted from that of
hBACS-transfected cells. At each of five C16:0 concentrations
tested (range of 2.5– 40 M), there was no statistically significant increase in C16:0 activation by hBACS-transfected cells
compared with pcDNA3-transfected cells (p ⱖ 0.1, n ⫽ 3; data
not shown). It is therefore unlikely that C16:0 is activated to a
significant degree by hBACS in vivo.
The kinetics of C16:0 and cholate activation by COS-1 cells
expressing hVLCS were also examined. When C16:0 was the
substrate, both pcDNA3- and hVLCS-transfected COS-1 cells
exhibited apparently normal Michaelis-Menten kinetics (Fig.
4B). Nonlinear regression analysis revealed a Km of 48 M and
a Vmax of 167 nmol/20 min/mg of COS cell protein for vectortransfected cells and a Km of 32 M and a Vmax of 175 nmol/20
min/mg of COS cell protein for cells expressing hVLCS. The
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FIG. 4. Kinetic analysis. COS-1 cells
expressing pcDNA3, hBACS, or hVLCS
were assayed for their ability to activate
the bile acid cholate (a preferred substrate for hBACS) or the long-chain fatty
acid palmitate (C16:0, a preferred substrate for hVLCS). A, [1-14C]cholate activation by hBACS exhibited typical
Michaelis-Menten kinetics. A Lineweaver-Burk double-reciprocal plot is
shown in the inset. Replicate data from
two independent transfections are plotted
on the same curve. Km and Vmax were
calculated by nonlinear regression analysis using GraphPAD Prism Version 3.02
for Windows. [1-14C]Cholate activation by
hVLCS was not detectable at any cholate
concentration tested (data not shown). B,
[1-14C]palmitate activation in vectortransfected COS-1 cells (●) or cells expressing hVLCS (Œ) exhibited apparently
normal Michaelis-Menten kinetics. The
contribution of hVLCS to the total C16:0
activation was estimated by subtraction
(䡺). A Lineweaver-Burk double-reciprocal plot is shown in the inset. Replicate
data from two independent transfections
are plotted on the same curve and were
analyzed by GraphPAD Prism software.
No C16:0-CoA synthetase activity in
hBACS-expressing cells that was statistically significantly different from that in
vector-transfected cells was measured.

contribution of hVLCS to the overall C16:0-CoA synthetase activity was estimated by subtraction (Fig. 4B), and a Km of 12 M
and a Vmax of 28 nmol/20 min/mg of COS cell protein were
calculated. It must be emphasized that these derived values
are, at best, crude estimates. In our previous study (7), we
found that neither vector-transfected nor hVLCS-transfected
COS-1 cells activate 20 M cholate to its CoA derivative. We
now report that no detectable activation was observed at any of
five concentrations of cholate tested (range of 2.5– 40 M) (data
not shown).
Hepatic Organization of VLCS- and BACS-expressing
Cells—We hypothesize that the primary metabolic role of
hBACS is bile acid activation. On the other hand, although
hVLCS may play a role in bile acid synthesis from THCA, this
enzyme can activate a wide variety of substrates, including
long-, very long-, and branched-chain fatty acids (7, 8). If these
two synthetases have different functions, the intrahepatic localization of cells expressing them might differ. We used in situ
hybridization to address this question in mouse liver. Using an
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FIG. 5. Hepatic expression pattern
of VLCS and BACS. Full-length cDNA
encoding the murine homolog of either
VLCS or BACS as template was used to
prepare sense and antisense RNA probes,
which were then hybridized with 8-m
frozen sections of normal adult mouse
liver as described under “Experimental
Procedures.” A and B, BACS antisense
probe; C, BACS sense probe; D and E,
VLCS antisense probe; F, VLCS sense
probe. Magnification ⫻100 (A, C, D, and
F) and ⫻200 (B and E).

FIG. 6. Topographic orientation of hVLCS and hBACS in endoplasmic reticulum membranes. COS-1 cells were transfected
with full-length hVLCS or hBACS constructs containing the c-myc
epitope in-frame at either the N or C terminus of the protein. Three
days following transfection, cells were fixed and permeabilized with
either Triton X-100 (exposing antigens facing both the cytoplasm and
the endoplasmic reticulum lumen) or digitonin (exposing antigens facing the cytoplasm only). Double-label indirect immunofluorescence
analyses using antibodies specific for the c-myc epitope and the endoplasmic reticulum luminal resident protein calreticulin were performed
as described under “Experimental Procedures.” The anti-myc antibody
was detected by a fluorescein-conjugated secondary antibody (green),
whereas the anti-calreticulin antibody was detected by a lissamine
rhodamine-conjugated secondary antibody (red). A–H, cells expressing
hVLCS; I–P, cells expressing hBACS. The position of the epitope tag (Nversus C-terminal) and the permeabilization method (Triton X-100 versus digitonin) are indicated on the right. Both C-myc-hBACS and Nmyc-hBACS were enzymatically active when expressed in COS-1 cells
(⬃50 and ⬃20% of untagged hBACS activity, respectively). N-mychVLCS and untagged hVLCS activated palmitic acid equally well, but
the activity of C-myc-hVLCS was ⬍20% than that of hVLCS. However,
the results of topographic experiments with hVLCS (untagged and
enzymatically active)-transfected cells and an antibody raised against
the C terminus of this protein gave results identical to those obtained
with C-myc-hVLCS and anti-myc antibody (7) (data not shown).

endoplasmic reticulum. We previously reported that the C terminus of endogenous hVLCS is oriented toward the peroxisomal matrix and not the cytoplasm (20). In contrast, both the
N-myc-hBACS (Fig. 6K) and C-myc-hBACS (Fig. 6O) proteins
could be detected in digitonin-permeabilized cells (compare
with calreticulin) (Fig. 6, L and P). These data suggest that
hBACS may preferentially act on substrates present in the
cytoplasm.
DISCUSSION

The synthesis of bile acids from cholesterol, conjugation with
amino acids, secretion into the bile and subsequently into the
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antisense RNA probe synthesized from cDNA encoding the
murine ortholog of hVLCS, we found that hepatocytes uniformly expressed this enzyme (Fig. 5, D and E). In contrast,
hepatocytes expressing the murine homolog of hBACS mainly
had a periportal distribution (Fig. 5, A and B). These observations are consistent with the differing proposed roles of the two
acyl-CoA synthetases in bile acid and fatty acid metabolism.
Topographic Orientation of hVLCS and hBACS Expressed in
COS-1 Cells—We previously reported that although hBACS is
primarily a microsomal enzyme, hVLCS is localized to both
peroxisomes and the endoplasmic reticulum (8, 20). Other laboratories have reported that activation of both bile acids (17,
18, 21) and the bile acid precursors DHCA and THCA (22)
occurs in microsomes. The fact that hBACS activates both bile
acids and THCA is consistent with these reports. Our observation that hVLCS, with its dual subcellular location, can activate THCA, but not bile acids, raised questions about the
precise role(s) of hVLCS and hBACS in bile acid synthesis.
An initial approach to answer this question was to examine
the topographic orientation of hVLCS and hBACS in the endoplasmic reticulum membrane. For these studies, epitope tags
were placed at either end of the expressed proteins. Full-length
hVLCS cDNA clones incorporating an in-frame myc epitope at
the N and C termini were constructed as outlined under “Experimental Procedures.” Similar myc-tagged constructs of
hBACS were prepared. COS-1 cells expressing these cDNAs
were examined by indirect immunofluorescence using anti-myc
antibody to determine the orientation of the expressed protein.
We previously reported that when COS-1 cells expressing
hVLCS are permeabilized with Triton X-100, the protein is
detected primarily in the endoplasmic reticulum, whereas the
endogenous protein is also detected in peroxisomes (8, 20).
COS-1 cells transfected with either N-myc-hVLCS (Fig. 6A) or
C-myc-hVLCS (Fig. 6E) also had a staining pattern consistent
with expression in the endoplasmic reticulum. The location was
confirmed by colocalization of immunofluorescence of hVLCS
with that of the endoplasmic reticulum luminal resident protein calreticulin (Fig. 6, B and F). Also as reported previously
(12), an endoplasmic reticulum N-myc-hBACS staining pattern
was observed in Triton X-100-permeabilized COS-1 cells expressing this protein (Fig. 6I). Cells expressing C-myc-hBACS
had an identical immunostaining pattern (Fig. 6M).
Permeabilization of cells with digitonin rather than Triton
X-100 yielded a somewhat different result. The C-myc-hVLCS
protein was detected in digitonin-permeabilized COS-1 cells
transfected with its cDNA (Fig. 6G), but N-myc-hVLCS was not
visualized (Fig. 6C). Under the conditions utilized, the luminal
protein calreticulin could not be detected (Fig. 6, D and H).
These data indicate that although the C terminus of hVLCS
faces the cytoplasm, the N terminus faces the lumen of the
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intestinal tract, reabsorption from the intestine, and reutilization require the integrated activity of multiple enzymes, organelles, and tissues. At two points in the hepatic phase of bile
acid metabolism, activation of the carboxylic acid side chain of
the steroid to a CoA derivative is required. First, in the pathway of de novo synthesis from cholesterol, the C27 precursors of
cholate and chenodeoxycholate (THCA and DHCA, respectively) must be converted to THCA-CoA and DHCA-CoA for
cleavage of three carbons from the side chain to occur. Second,
to conjugate the C24 bile acids cholate and chenodeoxycholate
to glycine or taurine, their carboxylic acid side chains must first
be activated to the corresponding CoA derivatives. The studies
reported here begin to address the nature of the acyl-CoA
synthetases that are involved in these two aspects of bile acid
metabolism.
Based on the biochemical and morphological data presented
here and our previous findings (7), we have developed a working hypothesis regarding the role(s) of hVLCS and hBACS in
bile acid metabolism (Fig. 7). Conversion of cholesterol to
THCA and DHCA requires several enzymatic steps that take
place in the endoplasmic reticulum, cytosol, and mitochondria
(1, 2). Activation of THCA and DHCA, precursors of cholic acid
and chenodeoxycholic acid, respectively, could be catalyzed by
either hVLCS or hBACS in the endoplasmic reticulum or by
hVLCS in peroxisomes. Once inside peroxisomes, the side
chains of THCA-CoA and DHCA-CoA are shortened by three
carbons via ␤-oxidation, yielding choloyl-CoA and chenodeoxycholoyl-CoA, respectively. The peroxisomal enzyme bile acylCoA:amino-acid N-acyltransferase (23) then catalyzes the formation of the glycine and taurine conjugates of cholic acid and
chenodeoxycholic acid. Exiting the peroxisome, the conjugated

bile acids are secreted into bile canaliculi and eventually reach
the small intestine. Although a large proportion of the conjugated bile acids remain intact, a small quantity undergoes
conversion in the bowel. Intestinal flora catalyze both deconjugation and dehydroxylation reactions (1, 2). 7␣-Dehydroxylation of cholate and chenodeoxycholate yields the secondary bile
acids deoxycholate and lithocholate, respectively. Intestinal
metabolism thus yields a mixture of primary and secondary
bile acids that includes both conjugated and free acids. Reabsorption of free bile acids occurs by passive diffusion throughout the small bowel (1, 24). When these free acids reach the
liver via the portal circulation, they must be reactivated and
then conjugated before they are returned to the bile. hBACS is
uniquely positioned in the endoplasmic reticulum membrane to
catalyze the reactivation reaction. Bile acyl-CoA:amino-acid
N-acyltransferase is found in the cytoplasm as well as the
peroxisome (17, 25). Following re-conjugation in the cytoplasm,
primary and secondary bile acids can be secreted into the bile
for reutilization. This hypothesis is consistent with that recently proposed by Solaas et al. (25), who investigated bile
acyl-CoA:amino-acid N-acyltransferase in human liver.
Using subcellular fractions from rat liver, other investigators
have shown that activation of THCA to its CoA derivative occurs
primarily in microsomes (22, 25). Our data indicate that both
hVLCS and hBACS are capable of activating THCA and that
both enzymes are found in the endoplasmic reticulum. Because
hVLCS is also found in peroxisomes (8, 20), it is not clear why
Schepers et al. (22) and Solaas et al. (25) did not detect significant
THCA activation in peroxisome-enriched liver fractions. Activation of THCA in peroxisomes rather than in microsomes is a more
attractive hypothesis because CoA derivatives generally do not
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FIG. 7. Proposed roles of VLCS and BACS in bile acid metabolism.
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A. K. Heinzer, P. A. Watkins, and K. D. Smith, unpublished data.

portal vein; thus, hBACS is well positioned to efficiently “scavenge” these bile acids, reactivating them for recycling. In contrast, hVLCS, which robustly activates fatty acids as well as
THCA, had a more uniform distribution throughout the liver
acinus.
The topographic orientation of hBACS, in which both the C
and N termini face the cytoplasm, also makes it well suited for
its proposed role in reactivation of bile acids returning to the
hepatocytes via the enterohepatic circulation. Analysis of the
hBACS amino acid sequence by the PHDhtm algorithm revealed that the protein contains no unequivocal transmembrane-spanning domains (35). The orientation of hVLCS in the
endoplasmic reticulum membrane, with the N terminus facing
the lumen and the C terminus facing the cytoplasm, is consistent with the model proposed by Smith et al. (26). These authors
suggested that VLCS is an integral membrane protein in microsomes. Schepers et al. (22) were unable to release THCACoA synthetase activity from microsomes using high salt alone,
consistent with the notion that VLCS and not BACS is primarily responsible for this synthetase activity.
In summary, in this report, we have described the ability of
two members of the VLCS/fatty acid transport protein family to
activate bile acids and their precursors. Based on these data,
we presented a working hypothesis regarding the roles of these
enzymes in bile acid metabolism. Solaas et al. (25) recently
hypothesized that the peroxisomal conversion of THCA to
choloyl-CoA is the rate-limiting step in production of conjugated bile acids via de novo synthesis. They further proposed
that the rate-limiting step in the reutilization of bile acids
returning to the liver via the enterohepatic circulation is the
reactivation step (25). Future studies will enable us to test
these hypotheses.
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Alternatively, if activation of THCA takes place solely in the
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is not clear at this time how either THCA or THCA-CoA enters
peroxisomes. Furthermore, it remains to be determined
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by VLCS or by BACS, if this process does not occur in peroxisomes. Data reported by Schepers et al. (22) on pH dependence
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